Physician profile
Peter A Slocum
NPI 1891788113
$2,316.29
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $221 · 2021: $549 · 2022: $726.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $565.90 | 2019-2020 | |
| Teleflex LLC | $550.07 | 2021-2022 | |
| Astellas Pharma US INC | $509.15 | 2019-2022 | |
| Pfizer INC. | $189.70 | 2019-2022 | |
| Urogen Pharma, INC. | $110.08 | 2021-2022 | |
| Janssen Biotech, INC. | $79.75 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $67.24 | 2019 | |
| Rochester Medical Corporation | $42.89 | 2021 | |
| Ferring Pharmaceuticals INC. | $38.72 | 2019 | |
| Dendreon Pharmaceuticals LLC | $26.77 | 2019 | |
| Blue Earth Diagnostics | $17.35 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.12 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.97 | 2019 | |
| Myriad Genetic Laboratories, INC. | $15.72 | 2022 | |
| Urovant Sciences INC | $15.01 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.82 | 2022 | |
| Cook Medical LLC | $13.82 | 2021 | |
| Abbvie INC. | $13.50 | 2022 | |
| Allergan, INC. | $11.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Slocum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.